Komori
Pharma Foods International (2929) · InitiativeAdvanced

Establishing a US Food Ingredient Sales Framework through GRAS Approval

First written in FY2022. 5 of 7 entries say "Advanced", first in 2026-06-10. Latest entry: FY2026.

7entries
5years
4from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2022 – FY20242022: 120222023: 020232024: 120242025: 020252026: 52026
Same theme, other companies
Revenue growth in the raw materials supply businessA theme 4 companies write about · 0 as a headwind · 5 as a tailwind

2 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「Preparations for obtaining GRAS status from the U.S. FDA, the U.S. Food and Drug Administration, have entered the final stage, and after approval, sales of PharmaGABA are expected to expand in the North American functional food and beverage market.」

    Development of Pharma GABA toward obtaining FDA GRAS certification in the United States has progressed to the final preparation stage.
  3. FY2024RestatedAnnual report

    「We will steadily advance development toward FDA GRAS approval in the United States for “ファーマギャバ.”」

    To establish a platform for selling food ingredients in the United States, development toward FDA GRAS approval for ファーマギャバ is continuing.
  4. FY2022First statedAnnual report

    「In the U.S. market, among overseas markets, we are establishing a platform for selling food ingredients in the United States by obtaining GRAS (Generally Recognized As Safe) status, a food safety designation, with the aim of delivering the company’s products to more people.」

    For food ingredient sales in the United States, the Company has specified for the first time that it will establish a sales platform through GRAS approval.
Moved together

"GABA Expansion in Japan and Overseas" moved the same way as this thread, in the same document, in 5 of its 7 moves.

555544★123456
  1. ★This thread
  2. 1GABA Expansion in Japan and Overseas5×
  3. 2Development of antibody therapeutics using proprietary chicken antibody technology5×
  4. 3SDG Initiatives Through the Upcycling of Underutilized Resources5×
  5. 4Joint research on CADASIL peptide drugs with the National Cerebral and Cardiovascular Center5×
  6. 5Development of Medicated Hair Growth Product Nyumo as a New Core Product4×
  7. 6Commercialization and Development Pipeline for New Functional Materials4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Pharma Foods International yet. It last moved in the General Meetings of Shareholders of 2026-10-02: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Establishing a US Food Ingredient Sales Framework through GRAS Approval | Pharma Foods International Co.,Ltd. (2929) | Komori